OBJECTIVE: We examined the utility of distinguishing between patients with frontotemporal lobar degeneration (FTLD) and Alzheimer disease (AD) using quantitative cerebral blood flow (CBF) imaging with arterial spin labeled (ASL) perfusion MRI. METHODS: Forty-two patients with FTLD and 18 patients with AD, defined by autopsy or CSF-derived biomarkers for AD, and 23 matched controls were imaged with a continuous ASL method to quantify CBF maps covering the entire brain. RESULTS: Patients with FTLD and AD showed distinct patterns of hypoperfusion and hyperperfusion. Compared with controls, patients with FTLD showed significant hypoperfusion in regions of the frontal lobe bilaterally, and hyperperfusion in posterior cingulate and medial parietal/precuneus regions. Compared with controls, patients with AD showed significant hypoperfusion in the medial parietal/precuneus and lateral parietal cortex, and hyperperfusion in regions of the frontal lobe. Direct comparison of patient groups showed significant inferior, medial, and dorsolateral frontal hypoperfusion in FTLD, and significant hypoperfusion in bilateral lateral temporal-parietal and medial parietal/precuneus regions in AD. CONCLUSIONS: Doubly dissociated areas of hypoperfusion in FTLD and AD are consistent with areas of significant histopathologic burden in these groups. ASL is a potentially useful biomarker for distinguishing patients with these neurodegenerative diseases.
OBJECTIVE: We examined the utility of distinguishing between patients with frontotemporal lobar degeneration (FTLD) and Alzheimer disease (AD) using quantitative cerebral blood flow (CBF) imaging with arterial spin labeled (ASL) perfusion MRI. METHODS: Forty-two patients with FTLD and 18 patients with AD, defined by autopsy or CSF-derived biomarkers for AD, and 23 matched controls were imaged with a continuous ASL method to quantify CBF maps covering the entire brain. RESULTS:Patients with FTLD and AD showed distinct patterns of hypoperfusion and hyperperfusion. Compared with controls, patients with FTLD showed significant hypoperfusion in regions of the frontal lobe bilaterally, and hyperperfusion in posterior cingulate and medial parietal/precuneus regions. Compared with controls, patients with AD showed significant hypoperfusion in the medial parietal/precuneus and lateral parietal cortex, and hyperperfusion in regions of the frontal lobe. Direct comparison of patient groups showed significant inferior, medial, and dorsolateral frontal hypoperfusion in FTLD, and significant hypoperfusion in bilateral lateral temporal-parietal and medial parietal/precuneus regions in AD. CONCLUSIONS: Doubly dissociated areas of hypoperfusion in FTLD and AD are consistent with areas of significant histopathologic burden in these groups. ASL is a potentially useful biomarker for distinguishing patients with these neurodegenerative diseases.
Authors: Greg J Stanisz; Ewa E Odrobina; Joseph Pun; Michael Escaravage; Simon J Graham; Michael J Bronskill; R Mark Henkelman Journal: Magn Reson Med Date: 2005-09 Impact factor: 4.668
Authors: Y Zhang; N Schuff; G-H Jahng; W Bayne; S Mori; L Schad; S Mueller; A-T Du; J H Kramer; K Yaffe; H Chui; W J Jagust; B L Miller; M W Weiner Journal: Neurology Date: 2007-01-02 Impact factor: 9.910
Authors: B C Dickerson; D H Salat; D N Greve; E F Chua; E Rand-Giovannetti; D M Rentz; L Bertram; K Mullin; R E Tanzi; D Blacker; M S Albert; R A Sperling Journal: Neurology Date: 2005-08-09 Impact factor: 9.910
Authors: Nathan A Johnson; Geon-Ho Jahng; Michael W Weiner; Bruce L Miller; Helena C Chui; William J Jagust; Maria L Gorno-Tempini; Norbert Schuff Journal: Radiology Date: 2005-03 Impact factor: 11.105
Authors: A T Du; G H Jahng; S Hayasaka; J H Kramer; H J Rosen; M L Gorno-Tempini; K P Rankin; B L Miller; M W Weiner; N Schuff Journal: Neurology Date: 2006-10-10 Impact factor: 9.910
Authors: Andrew Graham; Rhys Davies; John Xuereb; Glenda Halliday; Jillian Kril; Helen Creasey; Kim Graham; John Hodges Journal: Brain Date: 2005-01-05 Impact factor: 13.501
Authors: John M Ringman; Joseph O'Neill; Daniel Geschwind; Luis Medina; Liana G Apostolova; Yaneth Rodriguez; Barbara Schaffer; Arousiak Varpetian; Benjamin Tseng; Freddy Ortiz; Jaime Fitten; Jeffrey L Cummings; George Bartzokis Journal: Brain Date: 2007-05-23 Impact factor: 13.501
Authors: Jennifer L Whitwell; Clifford R Jack; Joseph E Parisi; David S Knopman; Bradley F Boeve; Ronald C Petersen; Tanis J Ferman; Dennis W Dickson; Keith A Josephs Journal: Brain Date: 2007-03-08 Impact factor: 13.501
Authors: Erik S Musiek; Yufen Chen; Marc Korczykowski; Babak Saboury; Patricia M Martinez; Janet S Reddin; Abass Alavi; Daniel Y Kimberg; David A Wolk; Per Julin; Andrew B Newberg; Steven E Arnold; John A Detre Journal: Alzheimers Dement Date: 2011-10-21 Impact factor: 21.566
Authors: Sudipto Dolui; Marta Vidorreta; Ze Wang; Ilya M Nasrallah; Abass Alavi; David A Wolk; John A Detre Journal: Hum Brain Mapp Date: 2017-07-24 Impact factor: 5.038
Authors: Pilar M Ferraro; Charles Jester; Christopher A Olm; Katerina Placek; Federica Agosta; Lauren Elman; Leo McCluskey; David J Irwin; John A Detre; Massimo Filippi; Murray Grossman; Corey T McMillan Journal: Neurobiol Aging Date: 2018-04-17 Impact factor: 4.673